Inovio Pharmaceuticals is trading at $1.45, down 10.48%, amid an active biotech-sector selloff.
- No verified company-specific announcement was listed for November 5; the latest company news was dated November 2.
- XBI is down 5.19%, with broader market declines adding pressure.
- The FDA approval of VOCERYQ was reported earlier and does not explain the current decline.